Kabir Nath, Chief Executive Officer, said, “We continue to make progress in our COMP360 phase 3 program, most recently with the authorization to commence recruitment in a number of European clinical trial sites. Both phase 3 trials, COMP005 and COMP006, are on track, and we expect to have initial top-line data in less than a year for COMP005. We also expect to see top-line data in our phase 2 study in PTSD by the end of this year. The August financing, led by specialist biotech investors, provides a strong financial foundation that permits COMPASS to move forward confidently with our clinical programs, as well as all supporting studies for a potential new drug application filing with the FDA. We also continue to invest in our pre-commercial work to ensure we are prepared for a successful COMP360 launch, if approved.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CMPS:
- COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
- Rising High: Exclusive talk with cannabis market research firm BDSA
- COMPASS Pathways announces CFO transition
- Compass Pathways announces CFO Falvey will depart, Hughes to be interim CFO
- COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023